

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.  
200.1079CON4APPLICATION NO  
10/056,348

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT  
Ronald M. BURCH et al.FILING DATE  
January 25, 2002GROUP  
1639

## U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE       | NAME         | CLASS | SUB-CLASS | FILING DATE IF APPROPRIATE |
|-------------------|-----------------|------------|--------------|-------|-----------|----------------------------|
| A01               | 4,690,927       | 09/01/1987 | Voss et al.  |       |           |                            |
| A02               | 4,844,907       | 07/04/1989 | Elger et al. |       |           |                            |
| A03               | 4,569,937       | 02/11/1986 | Baker et al. |       |           |                            |
| A04               | 5,190,947       | 03/02/1993 | Riess et al. |       |           |                            |

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

|     |  |
|-----|--|
| A05 | Statement Before the Food and Drug Administration's Arthritis Drugs Advisory Committee on the Nonsteroidal anti-inflammatory Drug Celecoxib. (HRG Publication #1465); December 1, 1998; obtained from <a href="http://www.citizen.org/publications/print_release.cfm?ID=6653">http://www.citizen.org/publications/print_release.cfm?ID=6653</a> on October 28, 2008. |
| A06 | NDA 020938 Approval letter and label April 13, 2000; obtained from <a href="http://www.accessdata.fda.gov">http://www.accessdata.fda.gov</a> on October 16, 2008   |
| A07 | NDA 20-938 Medical Review, completed August 31, 1999; obtained from <a href="http://www.accessdata.fda.gov">http://www.accessdata.fda.gov</a> on October 16, 2008  |
| A08 | NDA 20-938 Pharmacology Review(s), completed September 17, 1999; obtained from <a href="http://www.accessdata.fda.gov">http://www.accessdata.fda.gov</a> on October 16, 2008   |
| A09 | NDA 20-938 Clinical Pharmacology and Biopharmaceutics Review(s), 1999; obtained from <a href="http://www.accessdata.fda.gov">http://www.accessdata.fda.gov</a> on October 16, 2008   |
| A10 | NDA 20-938 Correspondence, 1998-1999; obtained from <a href="http://www.accessdata.fda.gov">http://www.accessdata.fda.gov</a> on October 16, 2008  |
| A11 | NDA 20-938 Administrative Documents, 1998; obtained from <a href="http://www.accessdata.fda.gov">http://www.accessdata.fda.gov</a> on October 16, 2008   |
| A12 | NDA 20-938 Chemistry Review(s), 1999; obtained from <a href="http://www.accessdata.fda.gov">http://www.accessdata.fda.gov</a> on October 16, 2008  |
| A13 | NDA 20-938 Microbiology Review(s) 1999; obtained from <a href="http://www.accessdata.fda.gov">http://www.accessdata.fda.gov</a> on October 16, 2008  |
| A14 | NDA 20-938 Statistical Review(s) 1999; obtained from <a href="http://www.accessdata.fda.gov">http://www.accessdata.fda.gov</a> on October 16, 2008   |
| A15 | Therapeutics Initiative, February 1995   |
| A16 | Therapeutics Initiative, January 1997  |
| A17 | Therapeutics Initiative, January/February 2001   |
| A18 | Prescribing Points, volume 8.4, June 1999  |
| A19 | Lichtblau, L. et al., "Pharmacologic management of cancer pain in rural Minnesota," <i>J Pain Symptom Manage</i> , Vol. 12, No. 5, p. 283-9, 1996.   |
| A20 | Wollheim, F.A., "Current pharmacological treatment of osteoarthritis," <i>Drugs</i> , Vol. 52, Suppl. 3, p. 27-38, 1996.   |
| A21 | Furst, D.E., "Meloxicam: selective COX-2 inhibition in clinical practice," <i>Semin Arthritis Rheum</i> , Vol. 26, No. 6, Suppl. 1, pp. 21-7, 1997.  |
| A22 | Capasso, Anna et al. "Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum" <i>European Journal of Pharmacology</i> Vol. 330, pp. 199-204, 1997.  |

| EXAMINER | DATE CONSIDERED |
|----------|-----------------|
|          |                 |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.